Session: 902. Health Services and Quality—Lymphoid Malignancies: Poster II
Hematology Disease Topics & Pathways:
Research, Lymphomas, B Cell lymphoma, Clinical Research, Diseases, real-world evidence, Lymphoid Malignancies
2,495 incident DLBCL patients were eligible for the study. The average follow up time after index was 41.7 months. During follow up 1,991 patients started a 1st line treatment, 868 a 2nd line treatment, and 354 a 3rd line treatment. Overall, patients spent on average 5.24 days per month in hospital after index. While on anti-cancer treatment this number increase to 9 in 1st line, 8.7 in 2nd line, and 9.4 in 3rd line treatment. Overall costs per patient per month (PPPM) were €3,695 after index. While on a treatment line, PPPM costs were €17,170 in 1st line, €13,362 in 2nd line, and €12,112 in 3rd line. Absolute costs sum up to is €59,868, €35,870, and €28,832 during 1st line, 2nd line, and 3rd line, respectively. Main cost drivers were hospitalizations (71% of total costs) and drug acquisition costs (18% of total costs).
The financial burden of DLBCL in Germany is high and there is a high medical need for new cost effective therapeutic options that can lower the disease burden and remain financially viable to support the growing number of patients with this aggressive disease.
Disclosures: Papadimitrious: Miltenyi Biomedicine GmbH: Current Employment. Mahlich: Miltenyi Biomedicine GmbH: Current Employment. Riou: Miltenyi Biomedicine GmbH: Current Employment. Werner: Team Gesundheit GmbH: Current Employment; Miltenyi Biomedicine GmbH: Other: Data Analysis.
See more of: Oral and Poster Abstracts